UNTREATED ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION , OR ESOPHAGEAL ADENOCARCINOMA
Clinical trials for UNTREATED ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION , OR ESOPHAGEAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNTREATED ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION , OR ESOPHAGEAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for UNTREATED ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION , OR ESOPHAGEAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy aims to fight tough stomach cancers
Disease control Recruiting nowThis study tests a new medicine (PF-08634404) combined with chemotherapy for people with advanced stomach, gastroesophageal junction, or esophageal cancer that has not been treated before. The trial has two parts: first checking safety and response, then comparing the new combo t…
Matched conditions: UNTREATED ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION , OR ESOPHAGEAL ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New hope for stomach cancer: experimental drug pumitamig faces off against standard immunotherapy
Disease control Recruiting nowThis study compares two treatment combinations for people with advanced or metastatic stomach, gastroesophageal junction, or esophageal cancer who have not had prior treatment. One group receives the experimental drug pumitamig plus chemotherapy, while the other receives the stan…
Matched conditions: UNTREATED ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION , OR ESOPHAGEAL ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated May 20, 2026 11:55 UTC